Neuroendocrine breast tumours: Breast cancer or neuroendocrine cancer presenting in the breast?

Adams, RF; Dyson, Paul J.; Barthelmes, Ludger

doi:10.1016/j.breast.2013.11.005

Cited by 51 publications

(60 citation statements)

References 56 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Lymph node involvement was recorded in 51% and distant metastases in 9% in the papers analysed by Adams et al in comparison with 39.6% and 9.3% within our material, respectively. TNM data is therefore moderately in line with the previous literature, although our material consisted only cases from 2007, which may contribute to smaller tumor size compared to data consisting also of older cases collected by Adams et al [4]. …”

Section: Discussionsupporting

confidence: 82%

“…Since gastrointestinal NEC is far more prevalent than NEBC, WHO emphasizes the exclusion of extramammary sites before the definite diagnosis of NEBC [1]. Adams et al [4] recently analysed comprehensively the literature meeting the 2012 WHO criteria for primary neuroendocrine breast tumors. They found 58 published articles, generating data for 108 cases including their own.…”

Section: Discussionmentioning

confidence: 99%

“…on the grade. The latest WHO diagnostic criteria for NEBC also emphasize the reliable exclusion of the possibility of metastatic neuroendocrine/small-cell carcinoma before a definite diagnosis since ≥97% of all neuroendocrine carcinomas derive from lungs or gastrointestinal tract [4]. The presence of ductal carcinoma in situ (DCIS) is supportive of origin in the breast [1].…”

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Primary neuroendocrine breast carcinomas are associated with poor local control despite favourable biological profile: a retrospective clinical study

et al. 2017

View full text Add to dashboard Cite

BackgroundBreast carcinomas with neuroendocrine features (NEBC) are a very rare entity of mammary neoplasms, WHO classification of which has recently been revised. There are very limited data available about the clinical behaviour and treatment options of NEBC.MethodsWe collected retrospectively patients with NEBC from Oulu and Helsinki University Hospitals in 2007–2015. There were 43 NEBC cases during the period.ResultsThe incidence of NEBC from all breast cancers varied from 0.1% in Helsinki to 1.3% in Oulu. The mean tumor size was 2.2 cm and 23 patients (55.8%) had no lymph node metastases when diagnosed. In total, 4 patients (9.3%) had distant metastases at the time of diagnosis. High estrogen receptor (ER) expression was observed in 41 (97.7%) patients. When non-metastatic NEBC were compared to a prospective set of ductal carcinomas (n = 506), NEBC were more often HER2 negative (p = 0.046), ER positive (p = 0.0062) and the NEBC patients were older (p < 0.0005) than patients with ductal carcinomas. Plasma chromogranin A correlated only to higher age at diagnosis (p = 0.0028). Relapse-free survival (p = 0.0013), disease-free survival (p = 0.024) and overall survival (p = 0.0028) favoured ductal carcinomas compared to NEBC, while no difference was observed in distant disease-free survival or in breast cancer-specific survival.ConclusionsThere is remarkable variation in the incidence of NEBC in Finland, which is likely to be explained by differences in the use of neuroendocrine marker immunostainings. Poor local control and worse overall survival may be linked to the more aggressive biology of the disease, despite its association with apparently indolent prognostic factors.

show abstract

Section: Discussionsupporting

confidence: 82%

Section: Discussionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Primary neuroendocrine breast carcinomas are associated with poor local control despite favourable biological profile: a retrospective clinical study

et al. 2017

View full text Add to dashboard Cite

show abstract

“…While similar characteristics between small cell carcinoma of the lung and small cell carcinoma of the breast are seen, there may be inherent biologic differences. Options for treatment of small cell carcinoma of the breast include surgery, adjuvant chemotherapy and radiation, and hormonal therapy with the options dependent on the stage and expression of receptors [1,8]. Due to the paucity of data, the optimal management of small cell carcinoma of the breast remains unknown.…”

Section: Introductionmentioning

confidence: 98%

Genomic landscape of small cell carcinoma of the breast contrasted to small cell carcinoma of the lung

McCullar

Pandey

Yaghmour

et al. 2016

Breast Cancer Res Treat

View full text Add to dashboard Cite

Small cell carcinoma of the breast is a rare, aggressive form of breast cancer that is associated with extremely poor outcomes [1]. In an effort to identify possible targets for treatment, we utilized comprehensive genomic profiling in small cell carcinoma of the breast. Under an IRB approved protocol, we identified patients with small cell carcinoma of the breast and small cell carcinoma of the lung profiled by Caris Life Sciences between 2007 and 2015. Tumors were assessed with up to 25 immunohistochemical stains, in situ hybridization of cMET, EGFR, HER2, PIK3CA, and TOP2A, and next generation sequencing as well as Sanger sequencing of 47 genes. 19 patients with small cell carcinoma of the breast were identified, median age was 58 years (range 37-79) and 42 % had metastatic disease at presentation; for comparison, 58 patients with small cell carcinoma of the lung were identified (66 [36-86], 65 % metastatic). By immunohistochemistry, 31 % of small cell carcinoma of the breast patients expressed ER, 13 % expressed PR, and 16 % expressed AR; small cell carcinoma of the lung patients expressed ER 0 %, PR 2 %, and AR 6 %. Small cell carcinoma of the breast and small cell carcinoma of the lung patients had similar patterns of other immunohistochemical expression (0 v 0 % PDL1, 50 v 42 % PD1, and 77 v 95 % TOP2A, respectively). All small carcinoma of the breast and small cell carcinoma of the lung patients were negative for HER2 and cMET amplification by in situ hybridization. Next generation sequencing revealed TP53 mutations in 75 % of patients both with small cell carcinoma of the breast and small cell carcinoma of the lung and PIK3CA mutations in 33 % of small cell carcinoma of the breast patients but no small cell carcinoma of the lung patients (Fisher's exact test p = 0.005, OR 0.02 [0.00-0.52]). No other mutations were found in small cell carcinoma of the breast patients and no other mutation occurred in over 10 % of small cell carcinoma of the lung patients except RB1 in 19 % (p = 0.31). Small cell carcinoma of the breast is an aggressive tumor with few therapeutic options. Molecular profiling suggests many similarities between small cell carcinoma of the breast and small cell carcinoma of the lung with the exception an increased incidence of PIK3CA mutations in small cell carcinoma of the breast, which may have therapeutic implications.

show abstract

“…Neuroendocrine tumors essentially originate in the broncho-pulmonary system and gastro-intestinal tract [1]. These tumors are rare.…”

Section: Introductionmentioning

confidence: 99%

Primary Neuroendocrine Carcinoma of the Breast: A Case Report and Review of the Literature

Bhiri¹,

Zaied²,

Mhabrech³

et al. 2017

OALib

View full text Add to dashboard Cite

show abstract

Neuroendocrine breast tumours: Breast cancer or neuroendocrine cancer presenting in the breast?

Cited by 51 publications

References 56 publications

Primary neuroendocrine breast carcinomas are associated with poor local control despite favourable biological profile: a retrospective clinical study

Primary neuroendocrine breast carcinomas are associated with poor local control despite favourable biological profile: a retrospective clinical study

Genomic landscape of small cell carcinoma of the breast contrasted to small cell carcinoma of the lung

Primary Neuroendocrine Carcinoma of the Breast: A Case Report and Review of the Literature

Contact Info

Product

Resources

About